ReviewGastroenterology report2022
Pregnancy and Crohn's disease: concerns and assurance of medical therapy.
Review in Gastroenterology report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis.Clinical and translational science · 2026Article
- Enhancing Crohn's disease management during pregnancy: innovations in therapeutic approaches and cutting-edge monitoring practices.BMC pregnancy and childbirth · 2025Observational
- Association between prenatal exposure to Crohn's disease and offspring psychiatric regulatory disturbances.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Pregnancy in Inflammatory Bowel Disease: Data from a Real-World Cohort in Germany.Journal of clinical medicine · 2024Article
- Choosing Therapy for Moderate to Severe Crohn's Disease.Journal of the Canadian Association of Gastroenterology · 2024Article
- Evolving treatment strategies in Crohn's disease.Gastroenterology report · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 50% of patients with inflammatory bowel disease including both Crohn's disease and ulcerative colitis are female with many being diagnosed and treated during their reproductive years. It is important for women to be in remission prior to and during pregnancy. There have been many advances in the treatment of inflammatory bowel disease, including new therapies. In this review, we summarize the currently approved medications for Crohn's disease and their safety in pregnancy and postpartum. The totality of evidence suggests that the majority of therapies are low-risk before and during pregnancy, and should be continued to control maternal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.